Trends in the Use and Role of Biomarkers in Phase I Oncology Trials
Bernardo H. L. Goulart(Massachusetts General Hospital), Bruce A. Chabner(Massachusetts General Hospital), Homer Pien(Massachusetts General Hospital), Thomas G. Roberts(Georgia Institute of Technology), Jeffrey W. Clark(Massachusetts General Hospital), Stan N. Finkelstein(Massachusetts Institute of Technology)
Cited by 113
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k